



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

July 30, 2015

Via E-mail  
Michael Smith  
Chief Financial Officer  
Raptor Pharmaceutical Corp.  
7 Hamilton Landing  
Suite 100  
Novato, California 94949

**Re: Raptor Pharmaceutical Corp.**  
**Form 10-K for the Fiscal Year Ended December 31, 2014**  
**Filed March 2, 2015**  
**Form 10-Q for the Quarterly Period Ended March 31, 2015**  
**Filed May 7, 2015**  
**File No. 000-25571**

Dear Mr. Smith:

We have completed our review of your filings. We remind you that our comments or changes to disclosure in response to our comments do not foreclose the Commission from taking any action with respect to the company or the filings and the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filings to be certain that the filings include the information the Securities Exchange Act of 1934 and all applicable rules require.

Sincerely,

/s/ Sharon M. Blume

Sharon M. Blume  
Accounting Branch Chief